New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompare5-Amino-1MQ vs Cartalax

5-Amino-1MQ vs Cartalax

Side-by-side comparison of key properties, dosing, and research.

Fat Loss & Metabolic
5-Amino-1MQ
Anti-Aging & Longevity
Cartalax
Summary
5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
Half-Life
Estimated 4–8 hours
Short (minutes); gene-regulatory effects are sustained
Admin Route
Oral
SubQ, Oral
Research
Typical Dose
50–100 mg
10 mg per day
Frequency
Once to twice daily
Daily for 10–30 days
Key Benefits
  • Raises intracellular NAD+ levels
  • Directly targets adipose tissue for fat reduction
  • Reduces fat cell size and differentiation
  • Increases basal metabolic rate
  • SIRT1 activation for metabolic regulation
  • No stimulant cardiovascular side effects
  • Synergistic with intermittent fasting and caloric restriction
  • May have anti-aging metabolic benefits
  • Supports cartilage matrix synthesis and maintenance
  • May slow progression of osteoarthritic cartilage degradation
  • Reduces chondrocyte apoptosis
  • Promotes joint longevity in aging and high-impact sports
  • Anti-aging effects on connective tissue
  • Complementary to BPC-157 and TB-500 in joint recovery protocols
  • Well tolerated in available human and animal research
Side Effects
  • Generally well-tolerated in available studies
  • Mild GI discomfort (rare)
  • Limited long-term human data
  • Generally well tolerated
  • Mild injection site reactions
  • No significant adverse events reported at standard doses
Stacks With